Home » Stocks » Cancer Genetics

Cancer Genetics, Inc. (CGIX)

Stock Price: $3.14 USD 0.03 (0.96%)
Updated Aug 11, 2020 10:53 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 7.10M
Revenue (ttm) 6.91M
Net Income (ttm) -3.27M
Shares Out 2.26M
EPS (ttm) -1.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $3.14
Previous Close $3.11
Change ($) 0.03
Change (%) 0.96%
Day's Open 3.08
Day's Range 3.08 - 3.16
Day's Volume 6,906
52-Week Range 1.92 - 9.50

More Stats

Market Cap 7.10M
Enterprise Value 4.79M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 2.26M
Float 2.01M
EPS (basic) -1.69
EPS (diluted) -1.60
FCF / Share -2.07
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 24,458
Short Ratio 0.62
Short % of Float 1.68%
Beta 2.08
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1.03
PB Ratio 1.02
Revenue 6.91M
Operating Income -5.76M
Net Income -3.27M
Free Cash Flow -4.36M
Net Cash 2.31M
Net Cash / Share 1.02
Gross Margin 52.16%
Operating Margin -83.37%
Profit Margin -47.30%
FCF Margin -63.03%
ROA -6.70%
ROE -90.13%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$90.00*
Low
90.0
Current: $3.14
High
90.0
Target: 90.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue7.314.9329.1227.0518.0410.206.614.303.022.52
Revenue Growth48.11%-83.06%7.66%49.94%76.88%54.3%53.67%42.46%19.74%-
Gross Profit3.601.8411.059.953.941.751.690.37-0.10-0.99
Operating Income-5.70-7.69-18.62-16.72-21.38-19.21-8.46-7.64-8.18-6.32
Net Income-6.71-20.37-20.88-15.80-20.18-16.64-12.37-6.67-19.89-8.41
Shares Outstanding1.930.910.690.530.340.310.160.040.040.04
Earnings Per Share-3.48-22.39-30.30-30.00-58.81-54.01-109.21-316.53-468.35-201.32
Operating Cash Flow-8.66-12.55-13.56-17.85-13.60-12.34-8.08-7.58-5.07-5.73
Capital Expenditures-0.03-0.02-1.28-0.49-1.01-1.37-0.26-0.16-0.27-0.16
Free Cash Flow-8.69-12.57-14.85-18.34-14.61-13.71-8.33-7.74-5.34-5.89
Cash & Equivalents4.230.519.899.8019.7631.8549.761.072.620.00
Total Debt1.662.5811.035.146.376.926.3815.1710.51-
Net Cash / Debt2.58-2.07-1.144.6713.3924.9443.38-14.10-7.890.00
Assets14.9035.4152.2242.4348.8847.1155.168.957.03-
Liabilities7.5228.6025.4616.8115.8712.559.6932.9326.10-
Book Value7.396.8026.7725.6233.0234.5545.46-23.98-19.07-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cancer Genetics, Inc.
Country United States
Employees 110
CEO John A. Roberts

Stock Information

Ticker Symbol CGIX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CGIX
IPO Date April 5, 2013

Description

Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company's clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, and human papillomavirus-associated cancers, which include cervical, anal, head, and neck cancers. It serves the biotechnology and pharmaceutical customers in the United States, Europe, and Australia. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.